Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

NCT05450965 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Small-cell Lung Cancer
Small Cell Lung Carcinoma

Interventions

DRUG: Onvansertib

Sponsor

University of Maryland, Baltimore

Collaborators

[object Object]
[object Object]